Tag: Celgene

Amgen Completed $13.4bn Deal to Acquire Worldwide Rights to Otezla

amgen
Amgen announced that it completed its $13.4-billion deal to acquire worldwide rights to the psoriasis drug Otezla (apremilast) from Celgene. As a result, it now anticipates full-year sales ranging fro...

US Competition Regulators Gave Green Light to BMS/Celgene Merger

bms
Bristol-Myers Squibb and Celgene’s merger looks set to close after US competition regulators finally gave the $74 billion deal the go-ahead. The merger has been given the go-ahead by the Federal Tr...

Editas Medicine Announced Amended Collaboration with Celgene Corporation

celgene
Editas Medicine, Inc., a leading genome editing company, announced an amended collaboration with Celgene Corporation under which the parties may research, develop, and commercialize autologous and all...

FDA Granted Approval to Celgene Reblozyl

The U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular...

Celgene Announces Results from Phase 3 Study of Investigational Therapy CC-486

celgene
Celgene Corporation announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of inv...

Celgene Announce Scientific Collaboration with DarwinHealth

celgene
DarwinHealth announced a multi-year scientific collaboration with Celgene Corporation to use algorithms based on quantitative systems biology, technologies that also underpin the evidence of diagnosis...

Immatics Biotechnologies and Celgene Signed Collaboration Deal Worth $1.59bn

Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers. Based in Germany...

FDA Approved Celgene INREBIC for Myelofibrosis Treatment

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (...

Celgene Settled Lawsuit Over Cancer Drugs

celgene
The New Jersey drug maker who was became part of a debate over the cost of prescription drugs when their former CEO ran for the United States Senate last year, has agreed to pay $55 million to settle ...

Celgene’s OTEZLA® for the of Oral Ulcers Associated with Behçet’s Disease Approved by FDA

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated...

BMS Provides Update on Celgene’s Merger

Bristol-Myers Squibb Company provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation. The Company remains actively engaged in discussions with...

Evotec and Celgene Expand its Alliance

Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the col...

Celgene Announced FDA and EMA Accepted Applications for Ozanimod

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multipl...

FDA Accepted BLA for Celgene’s Erythroid Maturation Agent

celgene
Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational...

Celgene Received FDA Approval for REVLIMID

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID® (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previo...

BMS Selling $19bn of Bonds to Buy Celgene

The U.S. drugmaker Bristol-Myers Squibb (BMS) is preparing to place $19 billion in bonds to fund the acquisition of the rival company Celgene Corp in the largest bond issue since the beginning of 2019...